organization · Reporting owner
Recurium Equity, LLC
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Zentalis Pharmaceuticals, Inc.
Report date October 28, 2020 · Filed October 30, 2020
Section 16 reporting ended · disclosed 2020-10-30. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 14,990 |
Reported balance
After 2020-10-28 transaction · row 1
1 source rowRow 1 · 2020-10-28 · Other · Disposed 4,147,940 · Balance 14,990 F1: Recurium Equity, LLC distributed these shares to its members on a pro rata basis, for no consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: Recurium Equity, LLC distributed these shares to its members on a pro rata basis, for no consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 28, 2020 Filed Oct 30, 2020 19:53 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | OtherCommon Stock | 4,147,940 | $0.00 | $0.00 |
DisclosureSEC source: 0001725160-20-000024 · wf-form4_160410197813004.xml · nonDerivative · entry 1 Recurium Equity, LLC · CIK 0001808095 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,990 F1 · kind: Recurium Equity, LLC distributed these shares to its members on a pro rata basis, for no consideration. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.